Baker Bros. Advisors’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Baker Bros. Advisors’s Portfolio TCRR Stock Details TCRR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-753,064	Closed	-$1.13M	–	112
2023 Q1	$1.13M	Hold	753,064	–	–	0.01%	98
2022 Q4	$752K	Hold	753,064	–	–	﹤0.01%	102
2022 Q3	$1.36M	Hold	753,064	–	–	0.01%	102
2022 Q2	$2.18M	Hold	753,064	–	–	0.01%	96
2022 Q1	$2.08M	Hold	753,064	–	–	0.01%	100
2021 Q4	$3.51M	Buy	753,064 +576,603	+327%	+$3.6M	0.02%	99
2021 Q3	$1.5M	Hold	176,461	–	–	0.01%	113
2021 Q2	$2.9M	Hold	176,461	–	–	0.01%	106
2021 Q1	$3.9M	Buy	176,461 +65,573	+59%	+$1.79M	0.02%	102
2020 Q4	$3.43M	Sell	110,888 -11,644	-10%	-$294K	0.01%	100
2020 Q3	$2.49M	Buy	+122,532	New	+$2.15M	0.01%	98

Baker Bros. Advisors's TCRR Position: Q2 2023 in Review

Baker Bros. Advisors sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 753,064 shares — an estimated $1.13M sold.

Baker Bros. Advisors first reported a position in TCRR in Q3 2020 and held it in 11 quarters. The position peaked at $3.9M in Q1 2021. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.

Baker Bros. Advisors reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Baker Bros. Advisors sold 753,064 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $1.13M.
Baker Bros. Advisors first reported a position in TCR2 Therapeutics Inc. Common Stock in Q3 2020 and held it in 11 quarters.
Baker Bros. Advisors's TCR2 Therapeutics Inc. Common Stock position peaked at $3.9M in Q1 2021.
0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.

Based on Baker Bros. Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.